In March 2026, the American College of Cardiology (ACC), American Heart Association
(AHA), and partnering societies released updated U.S. dyslipidemia
guidelines—marking a pivotal shift in how inherited cholesterol disorders are identified
and managed. These new recommendations place strong emphasis on earlier
detection, greater awareness of genetic risk, and more intensive treatment for patients
at the highest cardiovascular risk.
For individuals living with familial hypercholesterolemia (FH) or elevated lipoprotein(a)
[Lp(a)], these updates highlight the importance of timely testing and personalized care
strategies—especially when standard lipid‑lowering therapies are not enough.
Why the 2026 Guidelines Matter
Despite advances in cholesterol treatment, cardiovascular disease remains the leading
cause of death in the United States. A significant contributor is unrecognized inherited
risk, which can leave patients vulnerable to early and recurrent cardiovascular events
even when LDL‑C appears well controlled.
The 2026 guidelines seek to close this gap by:
– Expanding screening recommendations
– Identifying genetically driven risk earlier in life
– Defining lower LDL‑C targets based on patient risk
– Encouraging timely escalation of therapy for patients who remain high risk
Together, these updates aim to prevent disease progression—not just manage it after
events occur.
Universal Lp(a) Testing: Raising Awareness of Hidden Risk
For the first time, the guidelines recommend that all adults have their Lp(a) level
measured at least once in their lifetime.
Lp(a) is a cholesterol‑like particle that is:
– Largely genetically determined
– Stable over time
– Minimally affected by diet, exercise, or lifestyle changes
Elevated Lp(a) is now recognized as an independent risk factor for atherosclerotic
cardiovascular disease (ASCVD). Identifying high Lp(a) early on allows clinicians to
better stratify risk and implement earlier and more aggressive LDL‑C management,
particularly in patients with a history of cardiovascular disease.
For some patients with elevated Lp(a), achieving guideline‑recommended LDL‑C levels
may remain challenging despite optimized medication—highlighting the need for
additional treatment approaches in select cases.
Earlier Cholesterol Testing in Children and Families
The 2026 guidelines also reinforce the importance of early cholesterol screening in
children, particularly to identify familial hypercholesterolemia.
Key recommendations include:
– Universal lipid screening between ages 9–11
– Earlier testing in children with a family history of premature ASCVD or known FH
– Use of cascade screening to identify affected relatives
FH causes extremely high LDL‑C from birth and significantly increases the risk of early
heart disease if untreated. Early detection allows families and care teams to begin
management long before irreversible vascular damage occurs.
Lower LDL‑C Targets Reflect Higher Standards of Care
To support more personalized risk reduction, the guidelines define clear LDL‑C targets
based on cardiovascular risk:
– Very high risk: LDL‑C < 55 mg/dL
– High risk: LDL‑C ≤ 70 mg/dL
– Lower risk: LDL‑C ≤ 100 mg/dL
These lower thresholds acknowledge that “lower is better” for patients with established
ASCVD, FH, or additional risk enhancers such as elevated Lp(a).
However, not all patients are able to reach these goals with lifestyle modification and
pharmacologic therapies alone.
Addressing Persistent Risk with Advanced Therapies
For patients with FH or elevated Lp(a)—especially those with recurrent cardiovascular
events—the 2026 guidelines underscore the importance of treatment intensification.
In carefully selected patients, advanced therapies such as Liposorber® may play an
important role. Liposorber is designed to directly remove LDL‑C and Lp(a) from the
bloodstream, providing an option for patients who remain high risk despite maximally
tolerated standard therapy.
By lowering circulating atherogenic lipoproteins, Liposorber can help support continued
risk reduction in patients whose cholesterol challenges are driven by inherited factors
rather than lifestyle alone.
A Future Focused on Earlier Action
Ultimately, the 2026 U.S. dyslipidemia guidelines send a clear message:
Awareness leads to earlier testing. Earlier testing enables better outcomes.
For patients and families affected by inherited cholesterol disorders, these updates
reinforce the importance of:
– Knowing cholesterol numbers beyond LDL‑C
– Identifying genetic risk as early as possible
– Individualizing treatment approaches to address persistent cardiovascular risk
To learn more about the full guideline recommendations, visit the National Lipid
Association’s summary of the 2026 ACC/AHA Multisociety Dyslipidemia Guideline
For LIPOSORBER Indications for Use and other safety information, please visit:
liposorber.com/liposorber-safety-info
BMSMR-00055